Reports Q3 revenue $98.05M , consensus $110.02M. “We’re in a strong financial position due to growing demand for our commercial products, completion of our recent offering, and our disciplined expense and portfolio management,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “We’ve also made significant progress on our key clinical programs and highlighted new, interim data from UX143 for osteogenesis imperfecta, GTX-102 for Angelman syndrome, and UX701 for Wilson Disease at our Analyst Day in October demonstrating promising therapeutic potential in these larger indications with further updates to come in 2024.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RARE:
- Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
- Mereo BioPharma received $9M milestone payment from Ultragenyx in July
- Mereo BioPharma provides update on recent program developments
- Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)